Immunosuppression in Experimental Allergic Encephalomyelitis

  • L. Massacesi
  • A. L. Abbamondi
  • E. Castigli
  • L. Amaducci
Part of the NATO ASI Series book series (NSSA, volume 142)


Immunosuppressive agents are widely employed for clinical situations characterized by altered immunological reactivity and manifestations of autoimmunity. Because of the complex and poorly understood mechanism of these conditions, such use is not generally approved and remain largely investigational.


Myelin Basic Protein Experimental Allergic Encephalomyelitis Blood Brain Barrier Damage Lysosomotropic Agent Efferent Phase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abb J., Abb H. and Deinhardt F., 1982, Effect of retinoic acid on the spontaneous and interferon-induced activity of human natural killer cells, Int. J. Cancer, 30: 307.CrossRefGoogle Scholar
  2. Allen P.M. and Unanue E.R., 1984, Differential requirement for antigen processing by macrophages for lysozyme-specific T cell hybridomas, J. Immunol., 132: 1077.Google Scholar
  3. Alvord E.C., Kies M.W. and Suckling A.J., 1984, Experimental Allergic Encephalomyelitis: A useful model for Multiple Sclerosis. Liss, New York.Google Scholar
  4. Amaducci L., Massacesi L. and Abbamondi A.L., 1986, The control of experimental allergic encephalomyelitis with retinoic acid. Further studies. Proceedings of the International Symposium on Multiple Sclerosis, Rome, October 16–18. In press.Google Scholar
  5. Bolton C., Borel J. F., Cuzner M.L., Davison A.N. and Turner A.M., 1982; Immunosuppression by Cyclosporin A of Experimental Allergic Encephalomyelitis, J. Neurol. Sciences, 56: 147.CrossRefGoogle Scholar
  6. Borel J.F. and Ryffel B., 1985, The mechanism of action of Cyclosporin: a continuing puzzle. In Cyclosporin in autoimmune diseases, Schindler R. ed., Springer-Verlag, Berlin.Google Scholar
  7. Bollag W., 1983, Vitamin A and Retinoids: from nutrition to pharmacotherapy in dermatology and oncology. Lancet, 1: 860.CrossRefGoogle Scholar
  8. Brinckerhoff C. E., Coffey J.W. and Sullivan A.C., 1983, Inflammation and collagenase production in rats with adjuvant arthritis reduced with 13-cis-retinoic acid. Science, 221: 756.CrossRefGoogle Scholar
  9. Brosnan C.F., Cammer W., Norton W.T. and Bloom B.R., 1980, Proteinase inhibitors suppress the development of experimental allergic encephalomyelitis, Nature, 285: 235.CrossRefGoogle Scholar
  10. Cammisuli S. and Feurer C., 1984, The effect of cyclosporin-A and dihydrocy-closporin-D on the therapy and prophylaxis of experimental allergic encephalomyelitis. In: Experimental allergic encephalomyelitis: A useful model for Multiple Sclerosis, pp. 415–421, Alvord E.C., Kies M.W., Sukling A.J. eds. Liss, New York.Google Scholar
  11. Chatenoud L., Jonker M., Villemain F., Goldstein G. and Bach J. F., 1986, The human immune response to the KT3 monoclonal antibody is oli-goclonal, Science, 232: 1406.CrossRefGoogle Scholar
  12. Dennert G. and Lotan R., 1978, Effects of retinoic acid on the immune system: stimulation of T killer cell induction. Eur. J. Immunol., 8: 23.CrossRefGoogle Scholar
  13. DeDuve C., De Borsy T., Poole B., Trouet A., Tuldens P. and Van Hoof F., 1974, Lysosomotropic agents, Biochem Pharmacol., 23: 2495.CrossRefGoogle Scholar
  14. Dresser D.W., 1968, Adjuvanticity of Vitamin A, Nature, 217: 527.CrossRefGoogle Scholar
  15. Eylar E.H., 1980, The induction and suppression of EAE. In The suppression of experimental allergic encephalomyelitis, Davison A.N. and Cuzner M.L. eds., Academic Press, London.Google Scholar
  16. Firtz R.B., Chou C.H. and McFarlin D.E., 1984, Relapsing Murine Experimental Allergic Encephalomyelitis induced by MBP, J. Immunol., 130: 3–1024.Google Scholar
  17. Fontana A., Fierz W. and Wekerle H., 1984, Astrocytes present myelin basic protein to encephalitogenic T-cell lines. Nature, 307: 273.CrossRefGoogle Scholar
  18. Groenewengen G., Buurman W.A. and Van Der Linden, 1985, Lymphokine dependence of in vivo expression of MHC Class II antigens by endothelium, Nature, 316: 361.CrossRefGoogle Scholar
  19. Hinrichs D.J., Wegman K.W. and Peters B.A., 1983, The influence of Cyclosporin A on the development of actively induced and passively transferred experimental allergic encephalomyelitis, Cell. Immunol., 77: 202.CrossRefGoogle Scholar
  20. Levine S. and Wenk E.J., 1964, Allergic encephalomyelitis, a hyperacute form, Science, 146: 1681.CrossRefGoogle Scholar
  21. Matsumoto Y. and Fugiwara M., 1986, In situ detection of Class I and Class II Mayor Hystocompability Complex antigens in the rat central nervous system during experimental allergic encephalomyelitis. An immunohi-stochemical study, J.Neuroimmunol., 12: 265.CrossRefGoogle Scholar
  22. McCarron R.M., Kempski O., Spatz M. and McFarlin D.E., 1985, Presentation of myelin basic protein by murine cerebral vascular endothelial cells, J. Immunol., 134: 3100.Google Scholar
  23. Miossec P., Cavender D. and Ziff M., 1986, Production of interleukin 1 by human endothelial cells. J. Immunology, 136: 2486.Google Scholar
  24. Mokhtarian F., McFarlin D.E. and Raine C.S., 1985, Adoptive transfer of MBP sensitized T cells produces chronic relapsing demyelinating disease in mice. Nature, 309: 356.CrossRefGoogle Scholar
  25. Morrison S.L., Johnson M.J., Harzenberger. A. and Oi V.T., 1984, Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc. Nat 1. Acad. Sci., 81: 6891.Google Scholar
  26. Paterson P.Y., 1960, Transfer of allergic encephalomyelitis in rats by means of lymphonode cells, J. Exp. Med., 111: 119.CrossRefGoogle Scholar
  27. Paul W.E., 1984, Fundamental Immunology. Raven Press (New York).Google Scholar
  28. Pender M. P., and Sears T.A., 1984, The pathophysiology of acute experimental allergic encephalomyelitis in the rabbit. Brain, 107: 699.CrossRefGoogle Scholar
  29. Pender M.P. and Sears T.A., 1984, Involvement of the dorsal root ganglion in acute experimental allergic encephalomyelitis in the Lewis rat, J. Neurol. Sciences, 72: 231.CrossRefGoogle Scholar
  30. Podack E.R. and Konigsberg P.J., 1984, Cytolytic T cell granules. Isolation, structural, biochemical and functional characterization, J. Exp. Med., 160: 695.CrossRefGoogle Scholar
  31. Roels O.A., 1968, The influence of Vitamin A and E on lysosomes. In: Lysosomes in biology and pathology. J. T. Dingle and H. B. Fell Eds. North-Holland, Amsterdam.Google Scholar
  32. Sears E.S., McMullan G.D. and Sears P.D., 1986, The suppression of experimental allergic encephalomyelitis with difluoromethylornitine, Neurology, 36(S): 312.Google Scholar
  33. Shapiro P.E. and Endelson R.L., 1985, Effect of retinoids on the immune system. In: Retinoids: New Trends in Research and Therapy, R. Saurat ed., Karger, Basel.Google Scholar
  34. Smith M.E., 1977, Role of proteolytic enzymes in demyelination in Experimental Allergic Encephalomyelitis, Neurochem. Res., 2: 233.CrossRefGoogle Scholar
  35. Smith M.E. and Amaducci L.A., 1982, Observation on the effects of protease inhibitors on the suppression of EAE. Neurochemical. Research, 7: 541.CrossRefGoogle Scholar
  36. Spitznagel J.K. and Allison A.C., 1970, Model of action of adjuvants: reti-noid and other lysosome-labilizing agents as adjuvants. J. Immunol., 104: 119.Google Scholar
  37. Sporn M.B., Roberts A.B., Goodman D.S., 1984. The Retinoids, Academic Press, New York.Google Scholar
  38. Steinman L., Rosenbaum J.T., Sriram S. and McDevitt H.O., 1981, In vivo effects of antibodies to immune response gene products: prevention of experimental allergic encephalomyelitis. Proc. Natl. Acad. Sci., USA, 78: 7111.CrossRefGoogle Scholar
  39. Steinman L., 1986, Molecular approach towards a therapy for Multiple Sclerosis. Proceedings of the International Symposium on Multiple Sclerosis, Rome, October 16–18, in press.Google Scholar
  40. Swanborg R.H., 1975, Antigen induced inhibition of experimental allergic encephalomyelitis. III. Localization of an inhibiting site distict from the major encephalitogenic determinant of myelin basic protein, J. Immunol., 114: 191.Google Scholar
  41. Teitelbaum D., Webb C., Meshorer A., Arnon R. and Sela M., 1972, Protection against experimental allergic eencephalomyelitis, Nature, 240: 264.CrossRefGoogle Scholar
  42. Traugott U., Raine C.S. and McFarlin A.E., 1985, Acute experimental allergic encephalomyelitis in the mouse: immunopathology of the developing lesion. Cell Immunol., 91: 240.CrossRefGoogle Scholar
  43. Trinchieri G. and Perussia B., 1985, Immune interferon: a pleiotropic lymphokine with multiple effects, Immunol. Today, 6: 131.CrossRefGoogle Scholar
  44. Trotter J. and Smith M.E., 1984, Macrophage-mediate demyelination: the role of phospholipases and antibody. In Experimental Allergic Encephalomyelitis: a useful model for Multiple Sclerosis, Alvord E.C., Kies M. and Sukling A.J. eds., Liss, New York.Google Scholar
  45. Uhr J.W., Weissmann G. and Thomas L., 1963, Acute hypervitaminosis A in guinea pigs: II. Effects on delayed type hypersensitivity. Proc. Exp. Biol. Med., 112: 287.Google Scholar
  46. Unanue E. R. and Benacerraf B., 1984, Textbook of Immunology. Williams and Wilkins, Baltimore.Google Scholar
  47. Unanue E. R. and Allen P. M., 1986, Biochemistry and biology of antigen presentation by macrophages. Cell. Immunol., 99: 3.CrossRefGoogle Scholar
  48. Vass K., Lassmann H., Wisniewski H.M. and Iqbal K., 1984, Ultracytochemical distribution of MBP after injection into the cerebro-spinal fluid. J. Neurol. Sciences, 63: 423.CrossRefGoogle Scholar
  49. Zamvil S., Nelson P., Trotter J., Mitchell D., Knobler R., Fritz R. and Steinman L., 1985, T-cell clones specific for MBP induce chronic relapsing paralysis and demyelination. Nature, 317: 355.CrossRefGoogle Scholar
  50. Ziegler H.K. and Unanue E.R., 1982, Decrease in macrophage antigen catabo-lism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T. cells. Proc. Natl. Acad. Sci., USA, 79: 175.CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1987

Authors and Affiliations

  • L. Massacesi
    • 1
  • A. L. Abbamondi
    • 1
  • E. Castigli
    • 1
  • L. Amaducci
    • 1
  1. 1.Istituto delle Malattie NervoseMentali dell’Università di FirenzeFirenzeItaly

Personalised recommendations